BridgeBio Pharma recently reported a strong and accelerating launch of its heart drug Attruby, with rapid growth in unique patient prescriptions and prescribers, supported by compelling clinical ...
RareLabs, a division of AlphaRose Therapeutics, named Rob Freishtat, MD as CEO. Charles Hirner joined NuvemRx as SVP of ...
In a report released today, Danielle Brill from Truist Financial maintained a Buy rating on BridgeBio Pharma, with a price target of $102.00.
Hosted on MSN
Pfizer settles to delay Vyndamax generics until 2031
Pfizer has reached settlements with three generic drugmakers, pushing back U.S. market entry of Vyndamax copies until mid-2031, pending other litigation. The move preserves billions in annual revenue ...
BridgeBio Pharma, Inc. remains a Buy, driven by Attruby’s strong U.S. launch and favorable competitive dynamics. Learn more ...
A change to FDA clinical trial data review, Rocket sells its priority review voucher, and more biotech news from The Readout ...
The settlements delay the entry of generic copies of Pfizer’s Vyndamax by almost three years, stabilizing sales of a drug ...
According to TipRanks.com, Fischbeck is a 3-star analyst with an average return of 2.4% and a 57.2% success rate. Fischbeck covers the Healthcare sector, focusing on stocks such as Ardent Health ...
Pfizer inking the last of three settlements to postpone copycats to its transthyretin amyloid cardiomyopathy (ATTR-CM) med ...
Good afternoon, everyone, and thank you for joining BridgeBio Pharma's Second Quarter 2025 Earnings Call. With me today are Neil Kumar, our CEO; Matt Outten, our Chief Commercial Officer; and Tom ...
Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have ...
Adds Pfizer statement. BridgeBio (BBIO) fell 1.3% after originally gaining 11% as a court filing disclosed a settlement in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results